Save the date: Optimum’s 19th Annual Healthcare Investor Conference — 7 October 2027. We look forward to seeing you there! 📸 Were you there? Find your photos and have your say! Find your photos, download your favourites and share them on social media, and don’t forget to tag Optimum so we can see them too. […]
Patent grant further strengthens POLB 001’s global intellectual property portfolio 6 October 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that a South Korean patent relating to POLB 001 has been formally granted. The patent, entitled “Medicinal products and methods for […]
Sofinnova Partners closed oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies Sofinnova Partners a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the final close of Sofinnova MD Start IV at €82 million. The fund, which was oversubscribed, will help expand […]
European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease Neuraxpharm Group announced that the European Commission (EC) has granted marketing authorisation under exceptional circumstances for NEZGLYAL® (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients, […]
Positive interim review marks key milestone for POLB 001 clinical development 24 September 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the ongoing TOPICAL clinical trial will proceed as planned following a positive review of data from […]
